CTNJ Op-Ed – Drug Innovation Argument Cuts Both Ways

In his recent op-ed, John Burkhardt of Pfizer misses important points when he asserts that the governor’s proposed tax on excessive prescription drug price increases will harm innovation and jobs in Connecticut. He ignores that rising drug prices are making health insurance unaffordable. Overpriced drugs inhibit other innovation and job growth across Connecticut’s economy. He left out how profitable drugs are, and that much of the pharmaceutical innovation is paid for by taxpayers. A tax on very high price increases is easy to avoid when prices are fair. Read more